Loading clinical trials...
Loading clinical trials...
ParpVax2: A Phase II Study Of Maintenance Niraparib Plus Ipilimumab In Patients With Metastatic Pancreatic Cancer Whose Disease Has Not Progressed On Platinum-Based Therapy
Conditions
Interventions
Niraparib
FOLFIRI
+1 more
Locations
2
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Start Date
May 7, 2025
Primary Completion Date
June 1, 2028
Completion Date
January 30, 2029
Last Updated
September 16, 2025
NCT05360264
NCT01053013
NCT01715142
NCT02179970
NCT03529175
NCT02195180
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions